Q4 Earnings Forecast for COCP Issued By HC Wainwright

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Stock analysts at HC Wainwright issued their Q4 2026 EPS estimates for Cocrystal Pharma in a research report issued to clients and investors on Friday, October 9th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.15) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.65) per share.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.10 million.

Separately, Weiss Ratings cut Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cocrystal Pharma presently has an average rating of “Hold”.

Cocrystal Pharma Trading Down 0.9%

Shares of NASDAQ:COCP opened at $1.06 on Monday. The company has a market capitalization of $20.42 million, a PE ratio of -1.39 and a beta of 1.48. Cocrystal Pharma has a 12-month low of $0.76 and a 12-month high of $2.03. The business’s fifty day simple moving average is $1.13 and its 200-day simple moving average is $1.14.

About Cocrystal Pharma

Cocrystal Pharma, Inc is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins.

Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development.

Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015.